ea0056gp211 | Pituitary Clinical | ECE2018
de Filette Jeroen
, Andreescu Corina
, Cools Filip
, Bravenboer Bert
, Velkeniers Brigitte
Background: Monoclonal antibodies targeting CTLA-4 and PD-1/PD-L1 are promising for a wide range of advanced malignacies. These immune checkpoint inhibitors (ICI) provoke endocrine adverse events including hypopituitarism and primary thyroid disease.Methods: PubMed was searched through August 22nd, 2017, for relevant articles on endocrinopathies and ICI, by two reviewers independently (J.d.F. and C.A.). The weighted incidence and odds-ratio were estimate...